Tuesday, August 06, 2013 1:47:35 PM
Anyday now, perhaps today, we will break the 52w high and that's very bullish, among other technical factors.
Don't be 'scared' or put off buy the share price (the company also pays a dividend), as it will look awfully cheap when they come out of phase III Alzheimer clinicals with continuing dramatic success and eventual FDA approval. The revenue market for such a drug is staggering and my research says we've got a potential monster.
What I'm reading couldn't be more bullish and this is clearly a very high quality, world-wide drug research/development/marketing company, that one's portfolio should definitely be exposed to.
On the other end of the continuum, in terms of the staggering potential unmet medical need market out there, is a stem cell penny stock, ACTC, having consistently incredible success in the lab and now with humans, as the are about to enter accelerated phase II clinicals for Macular Degeneration and Stargadt's disease, affecting billions worldwide.
ACTC is to HLUYY what it was years ago as a developing r and d biotech.
An investor , imo needs to understand this developmental phenomenon in the growth and success of biotechs and have both in their portfolio.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM